Exploratory Analysis of PASADENA Open-label Extension Evaluating the Effect of Prasinezumab on the Progression of Motor Signs and Symptoms (S30.006)

Gennaro Pagano; Annabelle Monnet; Adriana Reyes; Tanya Simuni; Ronald B. Postuma; Nicola Pavese; Fabrizio Stocchi; Krzysztof Śmigórski; Valentina Gerbaldo; Riorge Thomas; Hanno Svoboda; Paulo Fontoura; Rachelle S. Doody; Geoffrey A. Kerchner; Patrik Brundin; Azad Bonni; Kenneth Marek; Tania Nikolcheva

doi:10.1212/wnl.0000000000205606

Abstract

This is the authors' abstract. We don't add key points for this paper.

To compare the progression of the PASADENA population treated with prasinezumab to a matched real-world data sample from the Parkinson's Progression Markers Initiative (RWD-PPMI).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pagano et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db6435876780cf https://doi.org/10.1212/wnl.0000000000205606

View at Publisher

Ask AI

Bookmark

Abstract

This is the authors' abstract. We don't add key points for this paper.

To compare the progression of the PASADENA population treated with prasinezumab to a matched real-world data sample from the Parkinson's Progression Markers Initiative (RWD-PPMI).

Exploratory Analysis of PASADENA Open-label Extension Evaluating the Effect of Prasinezumab on the Progression of Motor Signs and Symptoms (S30.006)

Abstract

Discussion

Cite This Study

Exploratory Analysis of PASADENA Open-label Extension Evaluating the Effect of Prasinezumab on the Progression of Motor Signs and Symptoms (S30.006)

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology